Article Text

Download PDFPDF
Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment
  1. V Tuseth1,
  2. H J Jaatun1,
  3. K Dickstein2
  1. 1Cardiology Division, Stavanger University Hospital, Stavanger, Norway
  2. 2University of Bergen, Cardiology Division, Central Hospital of Rogaland
  1. Correspondence to:
    Vegard Tuseth MD
    Cardiology Division, Central Hospital of Rogaland, 4068 Stavanger, Norway;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Intravenous amiodarone is a recognised treatment alternative for the conversion of atrial fibrillation to sinus rhythm.1–3 Consensus regarding dosage and duration of treatment has not been reached.4,5 Our coronary care unit routinely uses intravenous amiodarone for conversion of supraventricular arrhythmia in various clinical settings. Following a loading dose of 300 mg/30 mins, two alternative dosages of intravenous maintenance treatment—50 mg/hour and 100 mg/hour—employed. We compared the efficacy and safety of these two regimens in an open randomised study.


Patients with atrial fibrillation or flutter with duration of less than 48 hours were included. Patients with ECG evidence of transmural ischaemia, class III antiarrhythmic treatment within 14 days, cardiogenic shock, uncontrolled thyroid disease, previous symptomatic bradycardia without pacemaker, and tachycardia based on atrioventricular (AV) re-entrant mechanisms were not included. Patients developing signs of haemodynamic decompensation were cardioverted.

The primary parameter was conversion to sinus rhythm. Secondary parameters were time to sinus rhythm and time to rate control. Heart rate, QT time, and PR interval at the time of conversion, were recorded continuously. Electrocardioversion before completion of the 24 hour period and interruption of study medication because of adverse experience were separate end points. Conduction abnormalities …

View Full Text


  • This study received financial support from the hospital research committee, and was approved by the regional ethics committee.